NASDAQ: PLRX
Pliant Therapeutics Inc Stock Ownership - Who owns Pliant Therapeutics?

Insider buying vs selling

Have Pliant Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Mike OuimetteGeneral Counsel Corp. Secy2025-01-2210,230$10.99
$112.46kSell
Bernard CouliePresident and CEO2025-01-1752,419$11.20
$587.15kSell
Keith Lamont CummingsChief Financial Officer2025-01-1720,148$11.20
$225.68kSell
Lily CheungChief Human Resource Officer2025-01-173,740$11.20
$41.89kSell
Eric LefebvreChief Medical Officer2025-01-1718,478$11.20
$206.97kSell
Mike OuimetteGeneral Counsel Corp. Secy2025-01-1713,270$11.20
$148.64kSell
Hans HullChief Business Officer2025-01-1715,936$11.20
$178.50kSell

1 of 1

PLRX insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when PLRX insiders and whales buy or sell their stock.

PLRX Shareholders

What type of owners hold Pliant Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Matthew G. Robinson26.18%16,069,177$22.66MInsider
Tang Capital Management LLC9.77%6,000,000$8.46MInstitution
Deep Track Capital LP8.80%5,399,681$7.61MInstitution
Blackrock Inc8.54%5,241,759$7.39MInstitution
Third Rock Ventures III LP7.32%4,495,238$6.34MInsider
Vanguard Group Inc5.43%3,334,575$4.70MInstitution
Morgan Stanley4.97%3,051,514$4.30MInstitution
Cormorant Asset Management LP4.89%3,000,000$4.23MInstitution
Blue Owl Capital Holdings LP4.84%2,969,199$4.19MInstitution
Ubs Group Ag4.31%2,645,546$3.73MInstitution

1 of 3

PLRX vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
PLRX68.78%31.22%Net Selling
VERU32.31%33.57%Net Buying
NTRB3.01%50.83%
VANI3.32%96.68%Net BuyingNet Buying
XBIT14.69%45.12%

Pliant Therapeutics Stock Ownership FAQ

Who owns Pliant Therapeutics?

Pliant Therapeutics (NASDAQ: PLRX) is owned by 94.31% institutional shareholders, 42.80% Pliant Therapeutics insiders, and 0.00% retail investors. Matthew G. Robinson is the largest individual Pliant Therapeutics shareholder, owning 16.07M shares representing 26.18% of the company. Matthew G. Robinson's Pliant Therapeutics shares are currently valued at $23.30M.

If you're new to stock investing, here's how to buy Pliant Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.